REDWOOD CITY, Calif.,
March 11, 2019 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty
pharmaceutical company focused on the development and
commercialization of innovative therapies for the use in medically
supervised settings, today announced that management will be
presenting at the Oppenheimer 29th Annual Healthcare
Conference to be held March 19
– 20. AcelRx management will provide an overview of the
business and company updates during the live presentation and will
be available for one-on-one investor meetings.
Details of the event are as follows:
Oppenheimer 29th Annual Healthcare Conference
Date:
Wednesday, March 20, 2019
Location: Westin Grand Central, New York,
NY
Presentation Time: 2:45 pm ET
(11:45 a.m. PT)
The conference presentation will be webcast live and can be
accessed through the Investors page at www.acelrx.com. For those
not available to listen to the live broadcast, a replay will
be archived for 90 days and available through the Investors page on
www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA (sufentanil sublingual tablet,
30 mcg), known as DZUVEO in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
one product candidate, Zalviso®(sufentanil sublingual tablet
system, SST system, 15 mcg) being developed as an innovatively
designed patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in medically supervised settings.
DZUVEO and Zalviso are both approved products in Europe. Zalviso is not approved in the U.S.
For additional information about AcelRx, please
visit www.acelrx.com.
Media
Contacts:
|
Investor
Contacts:
|
Theresa Dolge,
Evoke
|
Raffi
Asadorian, CFO, AcelRx
|
215-928-2748
|
investors@acelrx.com
|
theresa.dolge@evokegroup.com
|
|
Jessica Ross,
Evoke
|
Brian Korb,
Solebury Trout
|
215-928-2346
|
646-378-2923
|
jessica.ross@evokegroup.com
|
investors@acelrx.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-present-at-oppenheimer--co-inc-29th-annual-healthcare-conference-300810254.html
SOURCE AcelRx Pharmaceuticals, Inc.